Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
Dow
McKesson

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 5,612,460

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,612,460
Title: Active carbonates of polyalkylene oxides for modification of polypeptides
Abstract:Poly(ethylene glycol)-N-succinimide carbonate and its preparation are disclosed. Polyethylene glycol (PEG) is converted into its N-succinimide carbonate derivative. This form of the polymer reacts readily with amino groups of proteins in aqueous buffers. The modified proteins have PEG-chains grafted onto the polypeptide backbone by means of stable, hydrolysis-resistant urethane (carbamate) linkages.
Inventor(s): Zalipsky; Shmuel (Edison, NJ)
Assignee: Enzon, Inc. (Piscataway, NJ)
Application Number:08/198,193
Patent Claims:1. A modified polypeptide comprising a polypeptide and a polyalkylene oxide having a molecular weight of less than about 20,000 wherein said polyalkylene oxide is covalently bound to an amine group of the polypeptide by a urethane linkage formed by the process of

a) treating said polyalkylene oxide with phosgene to form a polyalkylene oxide chloroformate in situ;

b) reacting said polyalkylene oxide chloroformate with an N-hydroxy-N-dicarboximide followed by triethylamine to form a polyalkylene oxide having a terminal oxycarbonyl-oxy-N-dicarboximide group; and

c) reacting said polyalkylene oxide having a terminal oxycarbonyl-oxy-N-dicarboximide group with said polypeptide whereby said polypeptide and said polyalkylene oxide are covalently coupled said urethane linkage.

2. The modified polypeptide of claim 1, having the structure:

wherein R.sub.1 is CH.sub.3 or H, a is an integer selected so that the molecular weight of the polymer is less than about 20,000; and k is an integer.

3. The modified polypeptide of claim 1, wherein said polypeptide is selected from the group consisting of bovine serum albumin, glutaminase, trypsin, arginase, chymotrypsin, asparaginase and adenosine deaminase.

4. The modified polypeptide of claim 1, wherein said polyalkylene oxide having a terminal oxycarbonyl-oxy-N-dicarboximide group has the structure: ##STR8## wherein: R.sub.1 is H--, H.sub.3 C--, or an oxycarbonyl-oxy-N-dicarboximide; and .alpha. is an integer selected so that the molecular weight of said polyalkylene oxide is less than about 20,000.

5. The modified polypeptide of claim 1, wherein said polyalkylene oxide having a terminal oxycarbonyl-oxy-N-dicarboximide group has the structure: ##STR9## wherein: .alpha. is an integer selected so that the molecular weight of said polyalkylene oxide is less than about 20,000.

6. The modified polypeptide of claim 1, wherein said terminal oxycarbonyl-oxy-N-dicarboximide group comprises a member of the group consisting of N-succinimide, N-phthalimide, N-glutarimide, N-tetrahydrophthalimide and N-norborene-2,3-dicarboxide.

7. The modified polypeptide of claim 1, wherein reacting of said polypeptide with said polyalkylene oxide having said terminal oxycarbonyl-oxy-N-dicarboximide group is carried out at a pH in the range of 5.8-11.

8. The modified polypeptide of claim 1, wherein said polyalkylene oxide having said terminal oxycarbonyl-oxy-N-dicarboximide group is polyethylene glycol-succinidyl carbonate.

9. The modified polypeptide of claim 1, wherein said polyalkylene oxide having said terminal oxycarbonyl-oxy-N-dicarboximide group is polyethylene glycol-bis-succinidyl carbonate.

10. The modified polypeptide of claim 1, wherein said polyalkylene oxide has a molecular weight of about 2,000-20,000.

11. The modified polypeptide of claim 10, wherein said polyalkylene oxide has a molecular weight of about 5,000.

12. A polyethylene glycol-based conjugate comprising a urethane linkage attaching a protein or a polypeptide to a polyethylene glycol having a molecular weight of less than about 20,000 prepared by the process of:

a) treating said polyethylene glycol with phosgene to form a polyethylene glycol chloroformate in situ;

b) reacting said polyethylene glycol chloroformate with N-hydroxysuccinimide followed by triethylamine to form a N-succinimide carbonate derivatives of polyethylene glycol; and

c) reacting said N-succinimide carbonate derivatives of polyethylene glycol with said protein or said polypeptide whereby urethane linkages are formed attaching said N-succinimide carbonate derivatives of polyethylene glycol to amino groups on said protein or said polypeptide.

13. The polyethylene glycol-based conjugate of claim 12, wherein said N-succinimide carbonate derivatives of polyethylene glycol are reacted with said protein in aqueous buffers at a temperature of from 4.degree. to 40.degree. C.

14. The polyethylene glycol-based conjugate of claim 12, wherein said N-succinimide carbonate derivatives of polyethylene glycol are reacted with said protein in aqueous buffers having a pH of from 5.8 to 11.

15. The polyethylene glycol-based conjugate of claim 14, wherein said N-succinimide carbonate derivatives of polyethylene glycol are reacted with said protein in aqueous buffers having a pH of from 7.0 to 9.5.

Details for Patent 5,612,460

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Enzon, Inc. (Piscataway, NJ) 2014-03-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Mallinckrodt
Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.